CRIS Current Research Information System

BALDAZZI, CARMEN
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.373
NA - Nord America 5.289
EU - Europa 3.999
AF - Africa 360
SA - Sud America 238
Continente sconosciuto - Info sul continente non disponibili 22
OC - Oceania 9
Totale 15.290
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.195
VN - Vietnam 1.717
SG - Singapore 1.305
CN - Cina 1.223
GB - Regno Unito 1.030
SE - Svezia 631
IT - Italia 541
DE - Germania 489
HK - Hong Kong 318
FR - Francia 260
IN - India 232
RU - Federazione Russa 195
BR - Brasile 173
NL - Olanda 159
IE - Irlanda 141
KR - Corea 123
UA - Ucraina 94
FI - Finlandia 90
ZA - Sudafrica 88
JP - Giappone 86
TG - Togo 79
EE - Estonia 74
CI - Costa d'Avorio 64
CA - Canada 63
NG - Nigeria 58
CH - Svizzera 57
BG - Bulgaria 52
JO - Giordania 51
GR - Grecia 45
PH - Filippine 41
SC - Seychelles 41
IR - Iran 40
AR - Argentina 32
BE - Belgio 30
ID - Indonesia 28
TR - Turchia 28
BD - Bangladesh 26
IQ - Iraq 26
TH - Thailandia 26
PL - Polonia 22
AT - Austria 21
EU - Europa 21
MX - Messico 19
TW - Taiwan 18
ES - Italia 15
UZ - Uzbekistan 15
MY - Malesia 14
EC - Ecuador 11
HR - Croazia 10
AU - Australia 8
PY - Paraguay 8
RO - Romania 8
TM - Turkmenistan 8
LT - Lituania 7
PK - Pakistan 7
KE - Kenya 6
MA - Marocco 6
MU - Mauritius 6
SA - Arabia Saudita 6
CL - Cile 5
IL - Israele 5
LB - Libano 5
BB - Barbados 4
EG - Egitto 4
MK - Macedonia 4
PT - Portogallo 4
AL - Albania 3
JM - Giamaica 3
KH - Cambogia 3
KZ - Kazakistan 3
PE - Perù 3
PS - Palestinian Territory 3
SK - Slovacchia (Repubblica Slovacca) 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
CO - Colombia 2
CY - Cipro 2
CZ - Repubblica Ceca 2
KG - Kirghizistan 2
KW - Kuwait 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LV - Lettonia 2
NI - Nicaragua 2
NO - Norvegia 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
DK - Danimarca 1
DZ - Algeria 1
ET - Etiopia 1
GE - Georgia 1
GH - Ghana 1
GM - Gambi 1
GY - Guiana 1
HN - Honduras 1
HU - Ungheria 1
Totale 15.281
Salva come PNG Salva come JPEG
Città #
Southend 935
Singapore 923
Dong Ket 589
Ashburn 555
Chandler 470
Fairfield 417
Hong Kong 299
San Jose 284
Ann Arbor 257
Houston 241
Wilmington 238
Ho Chi Minh City 231
Hanoi 215
Seattle 202
Beijing 199
Woodbridge 196
Hefei 194
Princeton 165
Cambridge 153
Santa Clara 153
Dublin 141
Boardman 125
Seoul 103
New York 86
Nanjing 83
Lauterbourg 80
Lomé 79
Westminster 78
Bologna 75
Padova 71
Tokyo 68
Los Angeles 67
Abidjan 64
Helsinki 61
Medford 55
Milan 51
Amman 50
Berlin 50
Sofia 49
Bern 46
Munich 45
Abeokuta 39
Bremen 39
Shenyang 38
Jinan 37
Buffalo 35
Dallas 34
Haiphong 34
Saint Petersburg 34
Frankfurt am Main 33
Turin 33
São Paulo 32
Hebei 31
Nanchang 30
Brussels 29
Redondo Beach 28
Da Nang 27
Florence 26
Guangzhou 26
Changsha 25
Council Bluffs 25
Jacksonville 23
Hangzhou 22
San Diego 22
Shanghai 22
Orem 21
Paris 21
Redwood City 21
Bengaluru 19
Falls Church 19
Toronto 19
Falkenstein 18
Mountain View 17
Tianjin 17
Hải Dương 16
Istanbul 16
Johannesburg 16
Lappeenranta 16
Montreal 15
Rome 15
Athens 14
Jakarta 14
London 13
Nuremberg 13
Vienna 13
Zhengzhou 13
Baghdad 12
Biên Hòa 12
Chicago 12
Fuzhou 12
Jiaxing 12
Norwalk 12
Atlanta 11
Bangkok 11
Brooklyn 11
Haikou 11
Hyderabad 11
Phoenix 11
Tehran 11
Xi'an 11
Totale 9.673
Salva come PNG Salva come JPEG
Nome #
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 394
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 356
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 346
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 338
4q12 translocations with GSX2 expression identify a CD7+ acute myeloid leukaemia subset 333
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 306
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 295
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 288
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 276
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 254
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 254
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 250
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 250
Epigenetically induced ectopic expression of uncx impairs the proliferation and differentiation of myeloid cells 242
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 239
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 232
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 229
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 229
Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q) 227
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 215
A novel t(2;10)(q31;p12) balanced translocation in acute myeloid leukemia 212
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 212
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 210
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 207
Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival 205
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 204
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 204
t(5;12)(q31;p13)/ETV6::ACSL6 and t(6;9)(p23;q34)/DEK::NUP214 concurrence in acute myeloid leukemia: an unusual association of two rare abnormalities 201
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 200
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 197
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. 195
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 193
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 192
Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing 190
Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway 190
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 189
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 184
Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement:clinical implications 183
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 183
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 182
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia 179
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 178
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 178
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 177
A New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene 176
RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia 175
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 174
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 174
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 172
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 163
Gas1 and Kif27 genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients 163
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 161
GAS1 AND KIF27 GENES ARE STRONGLY UP-REGULATED BIOMARKERS OF HEDGEHOG INHIBITION (PF-04449913) ON LEUKEMIA STEM CELLS IN PHASE I ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOID LEUKEMIA TREATED PATIENTS 159
You have accessA New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene 159
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 158
Separase overexpression defines a new subset of acute myeloma leukemia patients characterized by high CD34 and MYC levels 157
FGFR1 and KAT6A rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features 155
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome 155
Novel fusion transcripts identified by RNAseq cooperate with somatic mutations in the pathogenesis of acute myeloid leukemia 154
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy 154
Next-Generation Sequencing Analysis Revealed That BCL11B Chromosomal Translocation Cooperates with Point Mutations in the Pathogenesis of Acute Myeloid Leukemia 151
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: follow up of a single-center Italian compassionate use 150
Ultra-Deep Sequencing Strategy Is a Precious Tool to Find Small Clones Harbouring FLT3 Mutations in AML Patients 145
PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients 144
Emergence and Cytogenetic Clonal Evolution of Chromosome 7 Abnormalities in Myeloid Malignancies: Investigating the Role of Telomere Dysfunction 142
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 142
Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP) 135
Genome-Wide Analysis by High-Resolution SNP Array Identifies Novel Genomic Alterations in Acute Promyelocytic Leukemia (APL). 134
PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience 134
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: the Bologna experience 132
Pharmacological interaction and side effects in oncohaematology: a retrospective observational study 129
IKZF1 (IKAROS) DELETIONS IN BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ARE ASSOCIATED WITH AN IMPAIRED B-CELL DIFFERENTIATION AND POOR OUTCOME 129
Nelarabine Is Safe and Effective In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL): The Bologna Experience 128
PF-04449913 reverts multi drug resistance (MDR) by a strong down-regulation of ABCA2 and BCL2 on leukemia stem cells in phase I acute myeloid leukemia and chronic myeloid leukemia treated patients 128
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients 128
NELARABINE IS SAFE AND EFFECTIVE IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) AND LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 126
IDENTIFICATION OF FREQUENT GENOMIC ABNORMALITIES IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS USING SINGLE NUCLEOTIDE POLYMORPHISM ARRAYS 123
SINGLE NUCLEOTIDE POLYMORPHISM (SNP) ARRAYS IDENTIFIED FREQUENT GENOMIC ABNORMALITIES IN GENES INVOLVED IN DRUG TRANSPORT AND INHIBITION OF APOPTOSIS IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS 118
IKZF1 (IKAROS) DELETIONS ARE A CENTRAL EVENT IN THE PATHOGENESIS OF BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA 116
NILOTINIB 400 MG BID IN EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA: BEYOND 4 YEARS RESULTS REMAIN STABLE - THE GIMEMA CML WP TRIAL CML0307 112
IKZF1 (IKAROS) DELETIONS ARE INDEPENDENT ON THE PHILADELPHIA CHROMOSOME AND ARE ASSOCIATED WITH AN IMPAIRED B-CELL DIFFERENTIATION AND POOR OUTCOME IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS 104
Totale 15.557
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.703
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.703
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.862 252 43 101 180 179 103 37 95 95 150 328 299
2022/20231.979 220 311 118 258 134 159 47 108 329 49 153 93
2023/2024589 23 74 28 68 39 149 36 52 21 31 38 30
2024/20252.011 71 297 177 125 241 72 197 66 14 242 114 395
2025/20264.596 429 408 354 293 467 216 401 175 1.127 443 127 156
2026/202717 17 0 0 0 0 0 0 0 0 0 0 0
Totale 15.557